AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron’s $256M 23andMe Acquisition
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response…